WUGEN
Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cell malignancies.
WUGEN
Social Links:
Industry:
Biotechnology Therapeutics
Founded:
2018-01-01
Address:
St Louis, Missouri, United States
Country:
United States
Website Url:
http://www.wugen.com
Total Employee:
51+
Status:
Active
Total Funding:
172 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
Intermediate Capital Group
Intermediate Capital Group investment in Series B - Wugen
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Wugen
Lightchain
Lightchain investment in Series B - Wugen
Aisling Capital
Aisling Capital investment in Series B - Wugen
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - Wugen
Alpha Wave Global
Alpha Wave Global investment in Series B - Wugen
LYZZ Capital
LYZZ Capital investment in Series B - Wugen
Abingworth
Abingworth investment in Series B - Wugen
Tybourne Capital Management
Tybourne Capital Management investment in Series B - Wugen
Velosity Capital
Velosity Capital investment in Series B - Wugen
Official Site Inspections
http://www.wugen.com Semrush global rank: 9.54 M Semrush visits lastest month: 141
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Wugen"
Wugen - Crunchbase Company Profile & Funding
Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR …See details»
About us - Wugen
About Us OPTIMIZED BY EVOLUTION Wugen is developing off-the-shelf cellular therapies for cancer Our cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer …See details»
Wugen - The Org
Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies. …See details»
WUGEN Company Profile | Management and Employees List
Founded in 2018, Wugen Inc., is a biotechnology company developing a novel CAR-T therapy platform including an "off-the-shelf" fratricide-resistant CAR-T cell therapy for T-cell …See details»
WUGEN - Overview, News & Similar companies | ZoomInfo.com
Who is WUGEN. Founded in 2018, Wugen Inc., is a biotechnology company developing a novel CAR-T therapy platform including an "off-the-shelf" fratricide-resistant CAR-T cell therapy for T …See details»
Leadership - Wugen
Leadership Kumar Srinivasan, Ph. D., M.B.A. President & Chief Executive Officer Kumar Srinivasan, Ph.D., MBA, in his most recent role served as executive vice president and chief business officer at Turning Point Therapeutics with …See details»
Wugen - LinkedIn
Wugen is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer.See details»
Wugen Company Profile 2024: Valuation, Funding & Investors
Wugen General Information Description. Developer of a novel CAR-T therapy intended for treating T-cell malignancies. The company is developing the next generation of off-the-shelf memory …See details»
Wugen - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Jul 15, 2021: Series B - Wugen …See details»
Wugen Company Profile - Office Locations, Competitors, Revenue …
Wugen Summary. Company Summary. Overview. Wugen is a biotechnology company developing cancer treatment therapies. It focuses on creating immuno-oncology therapies to treat solid …See details»
Wugen - Contacts, Employees, Board Members, Advisors
Organization. Wugen . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Number of Board Member and Advisor Profiles 5. …See details»
Wugen Announces CEO Transition - Business Wire
Mar 21, 2023 Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. …See details»
Wugen to Present Clinical Data at the 2024 ASH Annual Meeting …
2 days ago Data Support Start of First Pivotal Trial for an Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell Therapy in Pediatric and Adult PatientsST. LOUIS and SAN DIEGO, …See details»
Investors - Wugen
Investors OPTIMIZED BY EVOLUTION Wugen is developing off-the-shelf cellular therapies for cancer Our cell therapy products originate from healthy donors and are optimized to enhance …See details»
WuXi ATU and Wugen Announce Manufacturing Partnership
Jun 16, 2022 PHILADELPHIA and ST. LOUIS, MO and SAN DIEGO, June 15, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, …See details»
New CEO, check. $172M round, check. Wugen's off-the-shelf cell ...
Jul 15, 2021 Moving forward, Wugen will start a global, multicenter study for WU-NK-101 and file an IND for its CAR-T program in T-cell leukemia and lymphoma later this year, Kemp said. …See details»
Wugen to Present Clinical Data at the 2024 ASH Annual Meeting …
3 days ago About Wugen . Wugen, Inc. is a clinical-stage U.S. biotechnology company developing the next generation of off-the-shelf CAR-T and memory natural killer (NK) cell …See details»
Cellipont Bioservices and Wugen Sign Agreement for the Clinical ...
Mar 14, 2024 The Woodlands, TX, and St. Louis, MO, March 14, 2024/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization …See details»
Press Releases - Wugen
May 20, 2024 Press Releases Wugen Presents New Preclinical Data Supporting the Safety and Efficacy of WU-CART-007 for T-Cell Malignancies at the 63rd Annual Society of Hematology …See details»